Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GNMX

Aevi Genomic Medicine (GNMX) Stock Price, News & Analysis

Aevi Genomic Medicine logo

About Aevi Genomic Medicine Stock (NASDAQ:GNMX)

Advanced Chart

Key Stats

Today's Range
$0.15
$0.18
50-Day Range
$0.17
$0.19
52-Week Range
$0.11
$0.35
Volume
2.95 million shs
Average Volume
3.16 million shs
Market Capitalization
$12.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive GNMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aevi Genomic Medicine and its competitors with MarketBeat's FREE daily newsletter.

GNMX Stock News Headlines

Plc Astrazeneca's Net Worth
Aevi Genomic Medicine, Inc.
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
See More Headlines

GNMX Stock Analysis - Frequently Asked Questions

Aevi Genomic Medicine, LLC (NASDAQ:GNMX) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aevi Genomic Medicine investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX), Protalix BioTherapeutics (PLX), iBio (IBIO), Immunomedics (IMMU) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/01/2018
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNMX
Previous Symbol
NASDAQ:MDGN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.77 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
1.38

Miscellaneous

Free Float
N/A
Market Cap
$12.89 million
Optionable
Optionable
Beta
1.13
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:GNMX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners